Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial
Campistol, J.M.; Carreño, Aín.; Morales, Jé.M.; Pallardó, L.; Franco, A.; Navarro, D.; Grinyó, J.M.; Montenegro, Jús.; Sánchez Fructuoso, A.I.; Romero, Rón.; Guirado, L.; Arias, M.; Nieto-Iglesias, J.; Esforzado, N.; Beltrán-Catalán, S.; Gómez-Alamillo, C.; Lauzurica, R.; Bengoa, I.; Facundo-Molas, C.
Transplantation 95(2): E6
2013
ISSN/ISBN: 0041-1337 PMID: 23325012 Document Number: 665269
Document emailed within 1 workday
Related Documents
Ito, C.; Akimoto, T.; Morishita, Y.; Yamamoto, H.; Ogura, M.; Yamazaki, T.; Miki, A.; Homma, S.; Kusano, E.; Asano, Y.; Nagata, D. 2015: Comparison of benefits to non-dialysis CKD patients between darbepoetin alpha and epoetin beta pegol Nihon Jinzo Gakkai Shi 57(7): 1233-1240Yuksel, O.H.; Yildirim, C.; Urkmez, A.; Ozbay, N.; Uruc, F.; Sahin, A.; Akan, S.; Verit, A. 2018: The effect of darbepoetin alfa on renal fibrosis in rats with acute unilateral ureteral obstruction Archivos Espanoles de Urologia 71(2): 212-221
Stratta, R.J.; Taylor, R.J.; Weide, L.G.; Sindhi, R.; Sudan, D.; Castaldo, P.; Cushing, K.A.; Frisbie, K.; Radio, S.J. 1996: A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients Transplantation Proceedings 28(2): 917-918
Gross, C.R.; Kreitzer, M.J.; Thomas, W.; Reilly-Spong, M.; Cramer-Bornemann, M.; Nyman, J.A.; Frazier, P.; Ibrahim, H.N. 2010: Mindfulness-based stress reduction for solid organ transplant recipients: a randomized controlled trial Alternative Therapies in Health and Medicine 16(5): 30-38
Mukherjee, S.; Lyden, E. 2006: Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series Hepato-Gastroenterology 53(70): 561-565
MacDonald, A.S.; Daloze, P.; Dandavino, R.; Jindal, S.; Bear, L.; Dossetor, J.B.; Klassen, J.; Stiller, C.R.; Lockwood, B.; Reeve, C.E. 1987: A randomized study of cyclosporine with and without prednisone in renal allograft recipients. Canadian Transplant Group Transplantation Proceedings 19(1 Part 3): 1865-1866
Piccoli, A.; Malagoli, A.; Komninos, G.; Pastori, G. 2002: Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia Journal of Nephrology 15(5): 565-574
Remberger, M.; Ringden, O.; Aschan, J.; Ljungman, P.; Lönnqvist, B.; Markling, L. 1994: Long-term follow-up of a randomized trial comparing T-cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients Transplantation Proceedings 26(3): 1829-1830
Stock, P.G.; Lantz, M.; Light, S.; Vincenti, F. 1996: In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients Transplantation Proceedings 28(2): 915-916
Sadek, S.; Medina, Jé.; Arias, M.; Sennesael, J.; Squifflet, J-Paul.; Vogt, B. 2002: Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: A prospective, multicenter, randomized study Transplantation 74(4): 511-517
Locatelli, F.; Vecchio, L.D. 2001: Darbepoetin alfa. Amgen Current Opinion in Investigational Drugs 2(8): 1097-1104
Ratcliffe, P.J.; Firth, J.D.; Higgins, R.M.; Smith, B.; Gray, D.W.; Morris, P.J. 1993: Randomized controlled trial of complete steroid withdrawal in renal transplant patients receiving triple immunosuppression Transplantation Proceedings 25(1 Part 1): 590
Minnerup, J.; Schäbitz, W-Rüdiger. 2010: Darbepoetin alfa and chronic kidney disease New England Journal of Medicine 362(7): 653
Hampl, H.; Kovesdy, C.P.; Kalantar-Zadeh, K. 2010: Darbepoetin alfa and chronic kidney disease New England Journal of Medicine 362(7): 654; Author Reply 655
Johnson, E.M.; Zimmerman, J.; Duderstadt, K.; Chambers, J.; Sorenson, A.L.; Granger, D.K.; Almond, P.S.; Fryer, J.p.; Leventhal, J.R.; Scarola, J.; Matas, A.J.; Canafax, D.M. 1996: A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients Transplantation Proceedings 28(2): 987
Harmon, W.E.; Stablein, D.; Alexander, S.R.; Tejani, A. 1991: Graft thrombosis in pediatric renal transplant recipients. A report of the North American Pediatric Renal Transplant Cooperative Study Transplantation 51(2): 406-412
Veys, N.; Dhondt, A.; Lameire, N. 1998: Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta Clinical Nephrology 49(1): 41-44
Kimball, P.M.; King, A. 2011: A novel post-transplant alloantibody surveillance and intervention strategy that improves graft outcomes in sensitized renal transplant recipients Clinical Transplants 2011: 369-372
Mirza, S.; Mahmud, S.N.; Abideen, Z.U.; Aziz, T.; Akhter, S.; Baloch, B.K. 2019: Overcoming the Immunological Barrier in Highly HLA Sensitized Renal Transplant Recipients - a Desensitization Experience from a Transplant Center in Pakistan JPMA. Journal of the Pakistan Medical Association 69(4): 584-587
Canafax, D.M.; Simmons, R.L.; Sutherland, D.E.; Fryd, D.S.; Strand, M.H.; Ascher, N.L.; Payne, W.D.; Najarian, J.S. 1986: Early and late effects of two immunosuppressive drug protocols on recipients of renal allografts: results of the Minnesota randomized trial comparing cyclosporine versus antilymphocyte globulin-azathioprine Transplantation Proceedings 18(2 Suppl 1): 192-196